Seeking Alpha
 

Kindred Biosciences, Inc. (KIN)

- NASDAQ
  • Mon, Aug. 10, 9:09 AM
    | Mon, Aug. 10, 9:09 AM | Comment!
  • Fri, May 8, 9:05 AM
    | Fri, May 8, 9:05 AM | Comment!
  • Thu, Mar. 12, 4:14 PM
    | Thu, Mar. 12, 4:14 PM | Comment!
  • Dec. 4, 2014, 7:24 AM
    • Thinly-traded nano cap Kindred Biosciences (NASDAQ:KIN) plummets 24% premarket on robust volume in response to its announcement that it is terminating its atopic dermatitis program, including its AtoKin study, in favor of more promising programs.
    • CEO Richard Chin says the main reason for the move is the rapid uptake of a recently-launched atopic dermatitis product that has raised the bar for future competitors. He doesn't believe AtoKin is differentiated enough to be a market leader.
    • Kindred has been in a down trend March. Shares have dropped almost 75% since the March 14 peak of $26.99.
    • BMO analyst Alex Arfaei says Kindred's decision is "incrementally positive" for Zoetis' (NYSE:ZTS) Apoquel, which could hit $300M in sales by 2019.
    | Dec. 4, 2014, 7:24 AM | 2 Comments
  • Nov. 13, 2014, 4:21 PM
    • Kindred Biosciences (NASDAQ:KIN): Q3 EPS of -$0.31 beats by $0.14.
    • Cash and equivalents of $106.4M.
    • Press Release
    | Nov. 13, 2014, 4:21 PM | Comment!
  • Sep. 3, 2014, 4:29 PM
    • Kindred Biosciences (KIN +0.7%) CFO Stephen S. Galliker retires effective August 29, 2014. He will serve as a consultant for up to two more years at a rate of $5,000 per month for up to 20 hours of service per month and $250 per hour for services beyond 20 hours. In year two of the contract, the company will pay him $250 per hour of service. Services per month are not to exceed 80 hours and the maximum outlay to Mr. Galliker is capped at $200K/year.
    | Sep. 3, 2014, 4:29 PM | 1 Comment
  • Aug. 21, 2014, 1:11 PM
    | Aug. 21, 2014, 1:11 PM | 1 Comment
  • Aug. 21, 2014, 9:10 AM
    | Aug. 21, 2014, 9:10 AM | Comment!
  • Aug. 20, 2014, 5:07 PM
    • Shares of Kindred Biosciences (NASDAQ:KIN) plummet 34% on robust volume in response to the company's disclosure that its lead product candidate, CereKin (diacerein), an interleukin-1 inhibitor for the control of pain and inflammation associated with osteoarthritis in dogs, failed to achieve its primary endpoint in a clinical trial.
    • The failure was due to a higher-than-expected placebo response rate and statistical variability. In the high dose (20 mg/kg) cohort, the response rate was comparable to human studies but the dropout rate was too high to achieve statistical significance.
    | Aug. 20, 2014, 5:07 PM | 2 Comments
  • Aug. 13, 2014, 5:26 PM
    • Kindred Biosciences (KIN -1.4%) Q2 results: Revenues: $0; Net Loss: ($8.1M) (-999%); Loss Per Share: ($0.42) (-223.1%); Quick Assets: $112.4M (+72.1%).
    • No financial guidance given.
    | Aug. 13, 2014, 5:26 PM | Comment!
  • Aug. 13, 2014, 4:47 PM
    • Kindred Biosciences (NASDAQ:KIN): Q2 EPS of -$0.42 misses by $0.07.
    • Press Release
    | Aug. 13, 2014, 4:47 PM | Comment!
  • Apr. 10, 2014, 12:45 PM
    | Apr. 10, 2014, 12:45 PM | 3 Comments
  • Apr. 3, 2014, 12:45 PM
    | Apr. 3, 2014, 12:45 PM | Comment!
  • Apr. 3, 2014, 8:15 AM
    • Shares of Kindred Biosciences (KIN) are off 5% premarket in response to the firm's public offering of $50M of common stock.
    • Proceeds will be used for R&D, acquisitions and general corporate purposes.
    • The company filed its S-1 on March 18.
    | Apr. 3, 2014, 8:15 AM | Comment!
  • Mar. 19, 2014, 7:28 AM
    • Kindred Biosciences (KIN) files an S-1 for a public offering of common shares. Gross proceeds will be ~$86M.
    • Proceeds to be used to accelerate and expand R&D, acquisitions and for general corporate purposes.
    • Price unannounced but total post-offering shares will total 16,227,120.
    • Consensus revenue estimate for 2015 is $5.9M.
    • 28 mutual funds have positions.
    | Mar. 19, 2014, 7:28 AM | Comment!
  • Mar. 7, 2014, 10:23 AM
    • Roth Capital downgrades recent IPO Kindred Biosciences (KIN) to Neutral due to valuation with a price target of $25. Shares currently exchange hands at $23.50.
    • KIN debuted in December. Share peaked at $26.89 on February 27, up 125% from its opening day close of $11.95.
    • 28 mutual funds have positions.
    | Mar. 7, 2014, 10:23 AM | Comment!
Visit Seeking Alpha's
KIN vs. ETF Alternatives
Company Description
Kindred Biosciences Inc is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. The Company's product candidates are SentiKind, KIND-010 and KIND-012.
Sector: Healthcare
Industry: Biotechnology
Country: United States